Our patented C-Flow™ continuous fermentation process is designed to produce large quantities of biopharmaceuticals with small scale inexpensive equipment, saving dramatically on costs.
The C-Flow™ process was developed using Clean Genome® E. coli strains expressing recombinant CRM197, a carrier protein used to enhance the immunogenicity of poorly immunogenic carbohydrates in conjugated vaccines.
CRM197 protein is also available for purchase
| Characteristic | Benefit |
|---|---|
| Compatible with continuous manufacturing. | Continuous manufacturing is the future gold standard of biopharmaceuticals production (Find out more from the FDA) |
| Small scale equipment – 10-liter fermenters can produce up to kilogram quantities: 1-liter fermenters may suffice for personalized medicine. | Production facility accommodated in as little as 200 square feet.
Correspondingly smaller scale purification equipment required. |
| Fast process development. | Multiple process variables can be tested in series in a single run.
Limited scale-up required. Faster time to market. |
| Uses fully defined minimal medium. | Reproducible production process, purification simplified. |
Scarab’s C-Flow™ process dramatically increases the production levels of CRM197 and gives consistent, reproducible results irrespective of the run time.
Production levels of CRM197 using Clean Genome® E.coli host versus other traditional production hosts
C-Flow™ with Clean Genome® E. coli ferments indefinitely, maintaining high levels of protein production
Traditional strains used in fed-batch fermentation support C-Flow™ protein production for only 1-2 days
Consistent production levels of CRM197 in C-Flow™ over a range of process run times
Reproducible production facilitates predictable results
Continuous fermentations of up to 65 days have been achieved
- Longer runs are more beneficial than a fed-batch approach which uses a single production run in very large vessels (> 1,000 litres) over several days